Evaluation and treatment of chagas disease in the United States

A systematic review

Caryn Bern, Susan P. Montgomery, Barbara L. Herwaldt, Anis Rassi, Jose Antonio Marin-Neto, Roberto O. Dantas, James H. Maguire, Harry Acquatella, Carlos Morillo, Louis V. Kirchhoff, Robert H Gilman, Pedro A. Reyes, Roberto Salvatella, Anne C. Moore

Research output: Contribution to journalArticle

Abstract

Context: Because of population migration from endemic areas and newly instituted blood bank screening, US clinicians are likely to see an increasing number of patients with suspected or confirmed chronic Trypanosoma cruzi infection (Chagas disease). Objective: To examine the evidence base and provide practical recommendations for evaluation, counseling, and etiologic treatment of patients with chronic T cruzi infection. Evidence Acquisition: Literature review conducted based on a systematic MEDLINE search for all available years through 2007; review of additional articles, reports, and book chapters; and input from experts in the field. Evidence Synthesis: The patient newly diagnosed with Chagas disease should undergo a medical history, physical examination, and resting 12-lead electrocardiogram (ECG) with a 30-second lead II rhythm strip. If this evaluation is normal, no further testing is indicated; history, physical examination, and ECG should be repeated annually. If findings suggest Chagas heart disease, a comprehensive cardiac evaluation, including 24-hour ambulatory ECG monitoring, echocardiography, and exercise testing, is recommended. If gastrointestinal tract symptoms are present, barium contrast studies should be performed. Antitrypanosomal treatment is recommended for all cases of acute and congenital Chagas disease, reactivated infection, and chronic T cruzi infection in individuals 18 years or younger. In adults aged 19 to 50 years without advanced heart disease, etiologic treatment may slow development and progression of cardiomyopathy and should generally be offered; treatment is considered optional for those older than 50 years. Individualized treatment decisions for adults should balance the potential benefit, prolonged course, and frequent adverse effects of the drugs. Strong consideration should be given to treatment of previously untreated patients with human immunodeficiency virus infection or those expecting to undergo organ transplantation. Conclusions: Chagas disease presents an increasing challenge for clinicians in the United States. Despite gaps in the evidence base, current knowledge is sufficient to make practical recommendations to guide appropriate evaluation, management, and etiologic treatment of Chagas disease.

Original languageEnglish (US)
Pages (from-to)2171-2181
Number of pages11
JournalJournal of the American Medical Association
Volume298
Issue number18
DOIs
StatePublished - Nov 14 2007

Fingerprint

Chagas Disease
Electrocardiography
Infection
Therapeutics
Physical Examination
Heart Diseases
Ambulatory Monitoring
Blood Banks
Knowledge Bases
Trypanosoma cruzi
Organ Transplantation
Virus Diseases
Barium
Cardiomyopathies
MEDLINE
Echocardiography
Gastrointestinal Tract
Counseling
History
HIV

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Bern, C., Montgomery, S. P., Herwaldt, B. L., Rassi, A., Marin-Neto, J. A., Dantas, R. O., ... Moore, A. C. (2007). Evaluation and treatment of chagas disease in the United States: A systematic review. Journal of the American Medical Association, 298(18), 2171-2181. https://doi.org/10.1001/jama.298.18.2171

Evaluation and treatment of chagas disease in the United States : A systematic review. / Bern, Caryn; Montgomery, Susan P.; Herwaldt, Barbara L.; Rassi, Anis; Marin-Neto, Jose Antonio; Dantas, Roberto O.; Maguire, James H.; Acquatella, Harry; Morillo, Carlos; Kirchhoff, Louis V.; Gilman, Robert H; Reyes, Pedro A.; Salvatella, Roberto; Moore, Anne C.

In: Journal of the American Medical Association, Vol. 298, No. 18, 14.11.2007, p. 2171-2181.

Research output: Contribution to journalArticle

Bern, C, Montgomery, SP, Herwaldt, BL, Rassi, A, Marin-Neto, JA, Dantas, RO, Maguire, JH, Acquatella, H, Morillo, C, Kirchhoff, LV, Gilman, RH, Reyes, PA, Salvatella, R & Moore, AC 2007, 'Evaluation and treatment of chagas disease in the United States: A systematic review', Journal of the American Medical Association, vol. 298, no. 18, pp. 2171-2181. https://doi.org/10.1001/jama.298.18.2171
Bern C, Montgomery SP, Herwaldt BL, Rassi A, Marin-Neto JA, Dantas RO et al. Evaluation and treatment of chagas disease in the United States: A systematic review. Journal of the American Medical Association. 2007 Nov 14;298(18):2171-2181. https://doi.org/10.1001/jama.298.18.2171
Bern, Caryn ; Montgomery, Susan P. ; Herwaldt, Barbara L. ; Rassi, Anis ; Marin-Neto, Jose Antonio ; Dantas, Roberto O. ; Maguire, James H. ; Acquatella, Harry ; Morillo, Carlos ; Kirchhoff, Louis V. ; Gilman, Robert H ; Reyes, Pedro A. ; Salvatella, Roberto ; Moore, Anne C. / Evaluation and treatment of chagas disease in the United States : A systematic review. In: Journal of the American Medical Association. 2007 ; Vol. 298, No. 18. pp. 2171-2181.
@article{d360a199b31e46218f9c2cab5bccee37,
title = "Evaluation and treatment of chagas disease in the United States: A systematic review",
abstract = "Context: Because of population migration from endemic areas and newly instituted blood bank screening, US clinicians are likely to see an increasing number of patients with suspected or confirmed chronic Trypanosoma cruzi infection (Chagas disease). Objective: To examine the evidence base and provide practical recommendations for evaluation, counseling, and etiologic treatment of patients with chronic T cruzi infection. Evidence Acquisition: Literature review conducted based on a systematic MEDLINE search for all available years through 2007; review of additional articles, reports, and book chapters; and input from experts in the field. Evidence Synthesis: The patient newly diagnosed with Chagas disease should undergo a medical history, physical examination, and resting 12-lead electrocardiogram (ECG) with a 30-second lead II rhythm strip. If this evaluation is normal, no further testing is indicated; history, physical examination, and ECG should be repeated annually. If findings suggest Chagas heart disease, a comprehensive cardiac evaluation, including 24-hour ambulatory ECG monitoring, echocardiography, and exercise testing, is recommended. If gastrointestinal tract symptoms are present, barium contrast studies should be performed. Antitrypanosomal treatment is recommended for all cases of acute and congenital Chagas disease, reactivated infection, and chronic T cruzi infection in individuals 18 years or younger. In adults aged 19 to 50 years without advanced heart disease, etiologic treatment may slow development and progression of cardiomyopathy and should generally be offered; treatment is considered optional for those older than 50 years. Individualized treatment decisions for adults should balance the potential benefit, prolonged course, and frequent adverse effects of the drugs. Strong consideration should be given to treatment of previously untreated patients with human immunodeficiency virus infection or those expecting to undergo organ transplantation. Conclusions: Chagas disease presents an increasing challenge for clinicians in the United States. Despite gaps in the evidence base, current knowledge is sufficient to make practical recommendations to guide appropriate evaluation, management, and etiologic treatment of Chagas disease.",
author = "Caryn Bern and Montgomery, {Susan P.} and Herwaldt, {Barbara L.} and Anis Rassi and Marin-Neto, {Jose Antonio} and Dantas, {Roberto O.} and Maguire, {James H.} and Harry Acquatella and Carlos Morillo and Kirchhoff, {Louis V.} and Gilman, {Robert H} and Reyes, {Pedro A.} and Roberto Salvatella and Moore, {Anne C.}",
year = "2007",
month = "11",
day = "14",
doi = "10.1001/jama.298.18.2171",
language = "English (US)",
volume = "298",
pages = "2171--2181",
journal = "JAMA - Journal of the American Medical Association",
issn = "0098-7484",
publisher = "American Medical Association",
number = "18",

}

TY - JOUR

T1 - Evaluation and treatment of chagas disease in the United States

T2 - A systematic review

AU - Bern, Caryn

AU - Montgomery, Susan P.

AU - Herwaldt, Barbara L.

AU - Rassi, Anis

AU - Marin-Neto, Jose Antonio

AU - Dantas, Roberto O.

AU - Maguire, James H.

AU - Acquatella, Harry

AU - Morillo, Carlos

AU - Kirchhoff, Louis V.

AU - Gilman, Robert H

AU - Reyes, Pedro A.

AU - Salvatella, Roberto

AU - Moore, Anne C.

PY - 2007/11/14

Y1 - 2007/11/14

N2 - Context: Because of population migration from endemic areas and newly instituted blood bank screening, US clinicians are likely to see an increasing number of patients with suspected or confirmed chronic Trypanosoma cruzi infection (Chagas disease). Objective: To examine the evidence base and provide practical recommendations for evaluation, counseling, and etiologic treatment of patients with chronic T cruzi infection. Evidence Acquisition: Literature review conducted based on a systematic MEDLINE search for all available years through 2007; review of additional articles, reports, and book chapters; and input from experts in the field. Evidence Synthesis: The patient newly diagnosed with Chagas disease should undergo a medical history, physical examination, and resting 12-lead electrocardiogram (ECG) with a 30-second lead II rhythm strip. If this evaluation is normal, no further testing is indicated; history, physical examination, and ECG should be repeated annually. If findings suggest Chagas heart disease, a comprehensive cardiac evaluation, including 24-hour ambulatory ECG monitoring, echocardiography, and exercise testing, is recommended. If gastrointestinal tract symptoms are present, barium contrast studies should be performed. Antitrypanosomal treatment is recommended for all cases of acute and congenital Chagas disease, reactivated infection, and chronic T cruzi infection in individuals 18 years or younger. In adults aged 19 to 50 years without advanced heart disease, etiologic treatment may slow development and progression of cardiomyopathy and should generally be offered; treatment is considered optional for those older than 50 years. Individualized treatment decisions for adults should balance the potential benefit, prolonged course, and frequent adverse effects of the drugs. Strong consideration should be given to treatment of previously untreated patients with human immunodeficiency virus infection or those expecting to undergo organ transplantation. Conclusions: Chagas disease presents an increasing challenge for clinicians in the United States. Despite gaps in the evidence base, current knowledge is sufficient to make practical recommendations to guide appropriate evaluation, management, and etiologic treatment of Chagas disease.

AB - Context: Because of population migration from endemic areas and newly instituted blood bank screening, US clinicians are likely to see an increasing number of patients with suspected or confirmed chronic Trypanosoma cruzi infection (Chagas disease). Objective: To examine the evidence base and provide practical recommendations for evaluation, counseling, and etiologic treatment of patients with chronic T cruzi infection. Evidence Acquisition: Literature review conducted based on a systematic MEDLINE search for all available years through 2007; review of additional articles, reports, and book chapters; and input from experts in the field. Evidence Synthesis: The patient newly diagnosed with Chagas disease should undergo a medical history, physical examination, and resting 12-lead electrocardiogram (ECG) with a 30-second lead II rhythm strip. If this evaluation is normal, no further testing is indicated; history, physical examination, and ECG should be repeated annually. If findings suggest Chagas heart disease, a comprehensive cardiac evaluation, including 24-hour ambulatory ECG monitoring, echocardiography, and exercise testing, is recommended. If gastrointestinal tract symptoms are present, barium contrast studies should be performed. Antitrypanosomal treatment is recommended for all cases of acute and congenital Chagas disease, reactivated infection, and chronic T cruzi infection in individuals 18 years or younger. In adults aged 19 to 50 years without advanced heart disease, etiologic treatment may slow development and progression of cardiomyopathy and should generally be offered; treatment is considered optional for those older than 50 years. Individualized treatment decisions for adults should balance the potential benefit, prolonged course, and frequent adverse effects of the drugs. Strong consideration should be given to treatment of previously untreated patients with human immunodeficiency virus infection or those expecting to undergo organ transplantation. Conclusions: Chagas disease presents an increasing challenge for clinicians in the United States. Despite gaps in the evidence base, current knowledge is sufficient to make practical recommendations to guide appropriate evaluation, management, and etiologic treatment of Chagas disease.

UR - http://www.scopus.com/inward/record.url?scp=36148997207&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=36148997207&partnerID=8YFLogxK

U2 - 10.1001/jama.298.18.2171

DO - 10.1001/jama.298.18.2171

M3 - Article

VL - 298

SP - 2171

EP - 2181

JO - JAMA - Journal of the American Medical Association

JF - JAMA - Journal of the American Medical Association

SN - 0098-7484

IS - 18

ER -